Short Summary
Hisense USA Corporation and Nokia Technologies Oy have settled their IPR dispute over U.S. Patent 7,532,808 and jointly request the Board to keep the settlement agreement confidential and terminate the proceeding as to Hisense.
Detailed Summary
In IPR2025-01439 concerning U.S. Patent No. 7,532,808, Hisense USA Corporation and Nokia Technologies Oy reached a settlement that resolves the dispute. The parties filed a joint motion requesting the Patent Trial and Appeal Board to treat the settlement and related patent agreement as business confidential information under 35 U.S.C. § 317 and 37 C.F.R. § 42.74, thereby limiting public access. They also seek to terminate the IPR proceeding with respect to Hisense, arguing that the settlement obviates the need for further adjudication.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Snap Inc. et al. vs Nokia Technologies Oy is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Samsung Display Co., Ltd. et al.vsPictiva Displays International Ltd.
Samsung Display Co., Ltd.'s IPR petition against Pictiva Displays International Ltd. was denied by the PTAB. The Board found that the petition lacked compelling merits and determined the dispute was better suited for District Court resolution due to complex claim construction issues.
SmartSky Networks, LLCvsGogo Business Aviation LLC et al.
SmartSky Networks has filed an IPR petition challenging all 19 claims of Gogo’s ‘600 ATG communication patent, asserting anticipation and obviousness over four prior‑art references.
Cisco Systems, Inc.vsQPRIVACY USA LLC
Cisco has filed a rehearing request after the PTAB director denied institution of its IPR on patent 11,106,824, arguing that a prior Sotera stipulation eliminates concerns of duplicate litigation. The petition cites Federal Circuit case law to support its position.
Sarepta Therapeutics, Inc. et al.vsGenzyme Corporation et al.
Sarepta has filed an IPR petition seeking to invalidate claims 3‑6 of Genzyme’s ’542 AAV formulation patent, alleging obviousness over multiple prior‑art references. The petition details how Wu, Konz, Croyle, and Potter collectively disclose all claim limitations.
Conjupro Biotherapeutics, Inc. et al.vsAscletis Pharma China Co. Ltd.
The PTAB granted institution for PGR2025-00057, allowing the challenger to proceed with trial against patent 12234236.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.